Search
MRx-4DP0004
go.drugbank.com/drugs/DB15751InvestigationalMRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.
Mixtures: BİOBER-ZN ORAL SÜSPANSİYON İÇEREN FLAKON, 5 ADETBriakinumab
go.drugbank.com/drugs/DB05459InvestigationalAs of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. … Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases.
Anti-SARS-CoV-2 IgY
go.drugbank.com/drugs/DB16356Investigational[L27381] To create these antibodies, chickens are injected in the chest with the spike protein, which is the surface protein of SARS-CoV-2; this results in an immune response mounted by the chickens towards … These antibodies are currently being investigated against COVID-19 in the trial NCT04567810 (Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV
Reposal
go.drugbank.com/drugs/DB13805ExperimentalReposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia.
Human interleukin-6
go.drugbank.com/drugs/DB15060InvestigationalHuman interleukin-6 is under investigation in clinical trial NCT03170245 (Adiponectin, IL-6 and hsC-RP in Relation to Carotid Intima-media Thickness in B-thalassemia Patients).
NV1020
go.drugbank.com/drugs/DB04969InvestigationalNV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.
Zaltoprofen
go.drugbank.com/drugs/DB06737InvestigationalA non-steroidal anti-inflammatory drug approved for use in Japan in 1993.
Allovectin-7
go.drugbank.com/drugs/DB17439InvestigationalAllovectin-7 or allovectin-7(r) is a lipid complex that contains the DNA sequences encoding HLA-B7 and beta-2 microglobulin. … It was discontinued after it failed to improve the objective response rate or overall survival versus first-line chemotherapy in malignant melanoma.[A255207]
AGS-004
go.drugbank.com/drugs/DB05742InvestigationalThis approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment. … A personalized immunotherapy addresses these issues because it is able to capture private viral mutations, providing a matched, complete immune response for each individual HIV patient.